VIDEO: Paxlovid effective for people with prior immunity, study shows
Click Here to Manage Email Alerts
LOS ANGELES — Paxlovid reduced the risk for severe COVID-19 hospitalization or death among people with existing immunity from a previous infection or vaccination, according to pooled trial data presented at IDWeek.
Earlier trials showed Paxlovid — nirmatrelvir plus ritonavir — significantly reduced the risk for hospitalization or death from COVID-19 among people at high risk for severe disease with no prior SARS-CoV-2 infection, as well as people who were either unvaccinated or vaccinated.
In particular, the EPIC-HR trial showed Paxlovid was more than 85% effective at preventing hospitalization and all-cause death among unvaccinated people at high risk for severe disease.
John M. McLaughlin, PhD, vice president for anti-infectives and COVID-19 and influenza vaccines at Pfizer, and colleagues analyzed data on 969 high-risk and SARS-CoV-2 seropositive participants from the phase 2/3 EPIC-HR trial and 631 high-risk and vaccinated participants from the phase 2/3 EPIC-SR trial comparing Paxlovid with placebo in each group.
Compared with participants who received a placebo, Paxlovid reduced the risk for hospitalization and death by 73.7% (95% CI, 21.4%-91.3%), any COVID-19 medical visit by 65% (95% CI, 24.4%-83.8%) and having severe COVID-19 symptoms by 22.1% (95% CI, 0.66%-38.9%), with the median time to symptom alleviation being 2 days shorter among people receiving Paxlovid compared with those receiving a placebo.
In the video, McLaughlin explains the study’s findings and treating high-risk patients with Paxlovid.
Collapse
McLaughlin JM, et al. Abstract 88. Presented at: IDWeek; Oct. 16-19, 2024; Los Angeles.
Read more about
Click Here to Manage Email Alerts